Find similar products:
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PL 20046/0101.
Voleze 4.6 mg/24 h transdermal patch / Voleze 9.5 mg/24 h transdermal patch
Voleze 4.6 mg/24 h transdermal patch
Voleze 9.5 mg/24 h transdermal patch
Rivastigmine
What is in this leaflet:
1. What Voleze is and what it is used for
2. What you need to know before you use Voleze
3. How to use Voleze
4. Possible side effects
5. How to store Voleze
6. Contents of the pack and other information
The active substance of Voleze is Rivastigmine.
Rivastigmine belongs to a class of substances called cholinesterase inhibitors. In patients with Alzheimer’s dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Voleze allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease.
Voleze is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
If this applies to you, tell your doctor and do not apply Voleze transdermal patches.
Talk to your doctor, pharmacist or nurse before using Voleze
If any of these apply to you, your doctor may need to monitor you more closely while you are on this medicine.
If you have not applied a Voleze patch for three days, do not apply the next one before you have talked to your doctor.
There is no relevant use of Voleze in the paediatric population in the treatment of Alzheimer’s disease.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Voleze might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson’s disease or to prevent travel sickness).
If you have to undergo surgery whilst using Voleze transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia.
Food, drink and alcohol do not affect the use of Voleze transdermal patches because rivastigmine enters the bloodstream through the skin.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant, the benefits of using Voleze transdermal patches must be assessed against the possible effects on your unborn child. Voleze transdermal patches should not be used during pregnancy unless clearly necessary.
You should not breast-feed during treatment with Voleze transdermal patches.
Your doctor will tell you whether your illness allows you to drive vehicles and use machines safely. Voleze transdermal patches may cause fainting or severe confusion. If you feel faint or confused do not drive, use machines or perform any other tasks that require your attention.
Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
Your doctor will tell you which Voleze transdermal patch is most suitable for you.
During the course of the treatment your doctor may adjust the dose to suit your individual needs.
If you have not applied a Voleze patch for three days, do not apply the next one before you have talked to your doctor.
Every 24 hours take off the previous patch before putting ONE new patch on to ONLY ONE of the following possible locations.
When changing the patch, you must remove the previous day’s patch before you apply the new one to a different location of skin each time (for example on the right side of your body one day, then on the left side the next day and on your upper body one day, then on your lower body the next day). Do not apply a new patch to that same skin area twice within 14 days.
Voleze patches are thin, translucent, plastic patches that stick to the skin. Each patch is sealed in a sachet that protects it until you are ready to put it on. Do not open the sachet or remove a patch until just before you apply it.
If it helps you, you may write, for example, the day of the week, on the patch with a thin ball point pen.
The patch should be worn continuously until it is time to replace it with a new one. You may wish to experiment with different locations when applying a new patch, to find ones that are most comfortable for you and where clothing will not rub on the patch.
Gently pull at one edge of the patch to remove it slowly from the skin.
You should wash your hands with soap and water after removing the patch. In case of contact with eyes or if the eyes become red after handling the patch, rinse immediately with plenty of water and seek medical advice if symptoms do not resolve.
If a patch falls off, apply a new one for the rest of the day, then replace it at the same time as usual the next day.
If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch. You may require medical attention. Some people who have accidentally taken too much rivastigmine have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. Slow heart beat and fainting may also occur.
If you find you have forgotten to apply a patch, apply one immediately. You may apply the next patch at the usual time the next day. Do not apply two patches to make up for the one that you missed.
Tell your doctor or pharmacist if you stop using the patch.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may have side effects more often when you start your medicine or when your dose is increased. Usually, the side effects will slowly go away as your body gets used to the medicine.
Take off your patch and tell your doctor straight away, if you notice any of the following side effects which could become serious:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Not known (frequency cannot be estimated from the available data)
Take off your patch and tell your doctor straight away, if you notice any of the side effects above.
Other side effects seen with Rivastigmine capsules or oral solutions which may occur with the patch:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Not known (frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date, which is stated on the carton and sachet after ‘EXP’. The expiry date refers to the last day of the month.
Store in the original package in order to protect from light.
Keep the transdermal patch in the sachet until use.
This medicinal product does not require any special temperature storage conditions.
Do not use any patch that is damaged or shows signs of tampering.
After removing a patch, fold it in half with the sticky sides on the inside and press them together. Return the used patch to its sachet and dispose of it in such a way that children cannot handle it. Do not touch your eyes with your fingers and wash your hands with soap and water after removing the patch. If your community burns domestic rubbish, you can dispose of the patch with your domestic rubbish. Otherwise, return used patches to a pharmacy, preferably in the original packaging.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is rivastigmine.
Voleze 4.6 mg/24 h transdermal patches:
Each patch releasing 4.6 mg rivastigmine per 24 hours is 5 cm2 and contains 9 mg rivastigmine.
Voleze 9.5 mg/24 h transdermal patches:
Each patch releasing 9.5 mg rivastigmine per 24 hours is 10 cm2 and contains 18 mg rivastigmine.
The other ingredients are:
Film: Polyester film
Fluoro-coated polyester film
Drug matrix: Acrylic adhesive, Acrylates copolymer
poly(butyl methacrylat-co-methyl methacrylat)
Adhesive matrix: Silicone adhesive
Printing ink: Black printing ink
Each transdermal patch is a thin patch consisting of three layers. The outer layer is translucent, white and black-printed with the following:
One transdermal patch is packed in one child-resistant and heat-sealed sachet. The patches are available in packs containing 7, 10, 30, 60 and 90 sachets and in multipacks containing 60 (2 x 30) and 90 (3 x 30) sachets.
Not all pack sizes may be marketed.
This medicinal product is authorised in the Member States of the EEA under the following names:
3411-001-002
Germany: Voleze 4,6 mg/24h Stunden transdermales Pflaster/Voleze 9,5 mg/24h Stunden transdermales Pflaster
United Kingdom: Voleze 4.6 mg /24h Transdermal patch/Voleze 9.5 mg/24h Transdermal patch
This leaflet was last revised in April 2025.